Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-514
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABBV-514 is an investigational afucosylated monoclonal antibody targeting the human CC motif chemokine receptor 8 (CCR8). It is being developed by AbbVie for the treatment of solid tumors, primarily non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), both as a monotherapy and in combination with other agents such as PD-1 inhibitors. The drug acts by binding to CCR8, which may result in immunomodulating and antineoplastic effects. Its primary route of administration is intravenous infusion[3][4][5][9].
- Other names
- anti-CCR8 monoclonal antibody ABBV-514anti-CCR-8 monoclonal antibody ABBV-514anti-CCR 8 monoclonal antibody ABBV-514
02
Targets
CCR8
Beyond the preview
Go deeper on ABBV-514.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-514.